FR183998 free base

Research use only, not for human use.

FR183998 free base is an inhibitor of Na+/Ca2+ Exchanger.

FR183998 free base is an inhibitor of Na+/Ca2+ Exchanger.(In Vitro):FR183998 free base has potent inhibitory effects on Na+/H+ exchanger in rat lymphocytes, rat platelets, and human platelets with IC50s of 0.3 nM, 6.5 nM, and 3.1 nM, respectively.(In Vivo):FR183998 free base (1 mg/kg, i.v.) reduces the increase in serum levels of alanine transaminase, aspartate transaminase, and lactate dehydrogenase induced by hepatic I/R, and prevents the incidences of hepatic necrosis, apoptosis, and neutrophil infiltration. FR183998 free base blocks the I/R-induced activation of the NF-κB, reduces induction of iNOS and inhibits the production of nitric oxide. FR183998 free base also decreases the expression of the iNOS gene antisense transcript in the liver of hepatic I/R rats.FR183998 free base (0.1 and 1.0 mg/kg, i.v.) shows no effect hemodynamic parameters, and does not affect mean blood pressure and heart rate in conscious rats. Pretreatment of 0.01, 0.032, 0.10 mg/kg FR183998 free base or posttreament of 0.032 and 0.10 mg/kg FR183998 free base via intravenous administration, dose-dependently reuces reperfusion-induced ventricular fibrillation (VF) and mortality in reperfusion-induced arrhythmias in anesthetized rats, with ED50s against VF of 0.015 mg/kg and 0.070 mg/kg, respectively. FR183998 free base also reduces myocardial infarct sizes, and suppresses the arrhythmias in anesthetized rats.

FR183998 free base is a Na+/H+-exchange inhibitor, with IC50s of 0.3 nM, 6.5 nM and 3.1 nM by measurement of pHi change in rat lymphocytes, rat and human platelets, respectively.

FR183998 (0.1 and 1.0 mg/kg, i.v.) shows no effect hemodynamic parameters, and does not affect mean blood pressure and heart rate in conscious rats. Pretreatment of 0.01, 0.032, 0.10 mg/kg FR183998 or posttreament of 0.032 and 0.10 mg/kg FR183998 via intravenous administration, dose-dependently reuces reperfusion-induced ventricular fibrillation (VF) and mortality in reperfusion-induced arrhythmias in anesthetized rats, with ED50s against VF of 0.015 mg/kg and 0.070 mg/kg, respectively. FR183998 also reduces myocardial infarct sizes, and suppresses the arrhythmias in anesthetized rats. FR183998 (1 mg/kg, i.v.) reduces the increase in serum levels of alanine transaminase, aspartate transaminase, and lactate dehydrogenase induced by hepatic I/R, and prevents the incidences of hepatic necrosis, apoptosis, and neutrophil infiltration. FR183998 blocks the I/R-induced activation of the NF-κB, reduces induction of iNOS and inhibits the production of nitric oxide. FR183998 also decreases the expression of the iNOS gene antisense transcript in the liver of hepatic I/R rats.

——

Others

Other Targets

——

——

——

239440-20-1

428.33

C17H19Cl2N5O2S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (583.65 mM)

CN(C)CCNC(=O)c1cc(cc(c1)-c1cc(Cl)sc1Cl)C(=O)NC(N)=N

——

(-20℃)

With Ice Pack

≥ 2 years